Inflammatory cytokine pathways and barrier integrity

Inflammatory cytokine pathways and barrier integrity represent the physiological and pathological interaction between immune signaling molecules and the structural proteins that maintain tissue compartmentalization. Key cytokines such as Tumor Necrosis Factor (TNF), Interleukin-1 beta (IL-1β), and Interleukin-17 (IL-17) are known to modulate the expression and assembly of tight junction proteins, including claudins and occludins (PMID: 30107276). When these pathways are overactive, they lead to increased paracellular permeability, often referred to as "leaky barrier," which is a central feature of diseases like Inflammatory Bowel Disease (IBD) and psoriasis (PMID: 28414302). Intracellular signaling through the Janus kinase (JAK)-STAT pathway is a major mediator of these cytokine-induced barrier changes (PMID: 31652562). Therapeutic targeting of this axis involves using monoclonal antibodies to neutralize cytokines or small molecules to inhibit signaling enzymes, thereby preventing barrier breakdown. For instance, TNF inhibitors like infliximab have been shown to restore intestinal barrier integrity in patients with Crohn's disease (PMID: 10406244). Monitoring these pathways often involves measuring biomarkers like fecal calprotectin or zonulin, which reflect the degree of barrier damage and inflammation (PMID: 26307028). However, systemic inhibition of these pathways carries risks, primarily related to impaired host defense and increased susceptibility to infections.

Other names

Cytokine-mediated barrier dysfunctionInflammatory-driven epithelial permeabilityImmune-epithelial crosstalkLeaky barrier signaling

Neutralization of pro-inflammatory cytokines or inhibition of downstream signaling (e.g., JAK-STAT) to prevent tight junction degradation and restore epithelial/endothelial barrier function.